<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321319</url>
  </required_header>
  <id_info>
    <org_study_id>COV02520124</org_study_id>
    <nct_id>NCT02321319</nct_id>
  </id_info>
  <brief_title>Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients</brief_title>
  <official_title>An Open-Label, Safety and Pharmacokinetic Study of Hydromorphone Hydrochloride Extended-Release Tablets (Once-Daily Hydromorphone) in Opioid-Tolerant Pediatric Subjects With Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pediatric study is designed to provide safety information, dosing guidelines, and a
      pharmacokinetic (PK) evaluation of once-daily hydromorphone hydrochloride (HCl)
      extended-release (ER) tablets in children with chronic painful conditions who are
      &quot;opioid-tolerant&quot; prior to enrollment under the Pediatric Research Equity Act (PREA) of 2003.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business decision - product discontinued
  </why_stopped>
  <start_date type="Actual">March 11, 2017</start_date>
  <completion_date type="Actual">February 4, 2019</completion_date>
  <primary_completion_date type="Actual">February 4, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>28 days</time_frame>
    <description>Clinically significant changes in vital signs, pulse oximetry, and/or clinical laboratory assessments, were recorded as AEs</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Hydromorphone HCl ER Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone HCl ER Tablets</intervention_name>
    <description>Hydromorphone hydrochloride (HCl) extended release tablet</description>
    <arm_group_label>Hydromorphone HCl ER Tablets</arm_group_label>
    <other_name>Exalgo, Jurnista</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. Male or female subjects aged 7 to 17 years.

          2. Chronic cancer or noncancer pain (requiring around-the-clock opioid treatment)
             currently managed with stable dose of oral or injectable opioid corresponding to at
             least 6 mg of hydromorphone per day for at least 5 days prior to first dose.

          3. Female subjects of child bearing potential must have negative serum pregnancy test
             result at Screening and Day 1. If sexually active must be surgically sterilized at
             least 12 months prior to Screening or use contraception at least 30 days prior to
             Screening and for the duration of study participation and for at least 30 days after
             the last dose of study drug.

          4. Male subjects, with reproductive potential, who are sexually active must agree to use
             an acceptable method of contraception for the duration of the study.

          5. Opioid-tolerant.

          6. Subjects must have established a favorable response to opioid therapy in reducing
             pain.

          7. Subjects must require a minimum dose of 4 mg (1 JURNISTA tablet) and a maximum dose of
             16 mg (1 EXALGO tablet) after determining 66% of the converted dose of hydromorphone
             HCl per day from an established conversion table.

          8. Able to swallow a whole tablet without breaking, crushing, chewing or dissolving.

          9. Expected to require extended opioid treatment for at least 1 week.

         10. Subjects must be able to communicate effectively with study personnel.

         11. Subjects and parents/legal guardian must be able and willing to follow all protocol
             requirements and study restrictions.

        Exclusion:

          1. Life expectancy of less than 4 weeks.

          2. History of allergy or any significant intolerance with opioid treatment or allergies
             to sulfites.

          3. Currently using opioid (transcutaneous) analgesic patches.

          4. History of drug or alcohol dependence.

          5. History of renal, hepatic, cardiovascular, or respiratory conditions that would
             contraindicate participation in this study.

          6. Plan to undergo a surgical procedure within 3 days of Day 1 and for the duration of
             subject participation in the study. Subjects undergoing minor surgical procedures (eg,
             central line insertion, biopsies) will be eligible for participation in the study.

          7. Exhibit hemodynamic instability.

          8. Have dysphagia, or difficulty swallowing whole tablets.

          9. Narrowing of the digestive tract, Short gut syndrome, inflammatory bowel disease,
             peritonitis, cystic fibrosis, Meckel's diverticulum, or past GI surgery.

         10. Hypothyroidism, Addison's disease, asthma (including exercise induced asthma)
             requiring daily inhalers, an enlarged prostate, epilepsy, low blood pressure, seizure
             disorder, high intracranial brain pressure, gallbladder problems, pancreatic disease,
             liver disease, or kidney disease.

         11. Ileostomy or paralytic ileus.

         12. Blood-product transfusion within 2 weeks of enrollment or expected to require
             transfusion during study.

         13. Participated in a study with an investigational drug or device in the past 30 days
             prior to screening.

         14. Known history of human immunodeficiency virus (HIV), hepatitis C virus (HCV) or
             hepatitis B virus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Leader</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jackson Memorial Hospital, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Professional Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Services, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 12, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <results_first_submitted>May 5, 2020</results_first_submitted>
  <results_first_submitted_qc>May 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2020</results_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02321319/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydromorphone HCl ER Tablets</title>
          <description>Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Product discontinued</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hydromorphone HCl ER Tablets</title>
          <description>Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>Clinically significant changes in vital signs, pulse oximetry, and/or clinical laboratory assessments, were recorded as AEs</description>
        <time_frame>28 days</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Hydromorphone HCl ER Tablets</title>
            <description>Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>Clinically significant changes in vital signs, pulse oximetry, and/or clinical laboratory assessments, were recorded as AEs</description>
          <population>All participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 days, including a 3-week extension</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hydromorphone HCl ER Tablets</title>
          <description>Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fever of unknown origin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information Call Center</name_or_title>
      <organization>Mallinckrodt</organization>
      <phone>800-556-3314 ext 5</phone>
      <email>clinicaltrials@mnk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

